When statistically comparing the HER2 expression of primary tumor and metastases between therapeutic groups, a significantly higher HER2-expression was observed in the trastuzumab-treated group (p = 0.003) and the AMD3100-treated group (p = 0.003) compared to the control group. The gene discussed is ERBB2; the disease is neoplasm.